Israel - English - Ministry of Health

vitamed pharmaceutical industries ltd - ceftazidime as pentahydrate - powder for solution for injection - ceftazidime as pentahydrate 1.000 g/vial - ceftazidime - ceftazidime-vit is indicated for the treatment of the infections listed below in adults and children including neonates (from birth).• nosocomial pneumonia• broncho-pulmonary infections in cystic fibrosis• bacterial meningitis• chronic suppurative otitis media• malignant otitis externa• complicated urinary tract infections• complicated skin and soft tissue infections• complicated intra-abdominal infections• bone and joint infections• peritonitis associated with dialysis in patient on capd.treatment of patients with bacteraemia that occurs in association with, or is suspected to be associated with, any of the infections listed above.ceftazidime may be used in the management of neutropenic patients with fever that is suspected to be due to a bacterial infection.ceftazidime may be used in the peri-operative prophylaxis of urinary tract infections for patients undergoing trans-urethral resection of the prostate (turp).the selection of ceftazidime should take into account its antibacterial spectrum, which is mainly restricted to aerobic gram negative bacteria.ceftazidime should be co-administered with other antibacterial agents whenever the possible range of causive bacteria would not fall within its spectrum of activity.consideration should be given to official guidelines on the appropriate use of antibacterial agents.

Australia - English - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - ceftazidime pentahydrate -

Australia - English - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - ceftazidime pentahydrate -

Israel - English - Ministry of Health

abic marketing ltd, israel - ceftazidime as pentahydrate - powder for solution for injection - ceftazidime as pentahydrate 1 g/vial - ceftazidime - ceftazidime - treatment of single or multiple infections caused by susceptible microorganisms.

United States - English - NLM (National Library of Medicine)

sandoz inc - ceftazidime (unii: 9m416z9qnr) (ceftazidime anhydrous - unii:dzr1ent301) - ceftazidime anhydrous 1 g - ceftazidime for injection, usp is indicated for the treatment of patients with infections caused by susceptible strains of the designated organisms in the following diseases: ceftazidime for injection, usp may be used alone in cases of confirmed or suspected sepsis. ceftazidime has been used successfully in clinical trials as empiric therapy in cases where various concomitant therapies with other antibiotics have been used. ceftazidime for injection, usp may also be used concomitantly with other antibiotics, such as aminoglycosides, vancomycin, and clindamycin; in severe and life-threatening infections; and in the immunocompromised patient. when such concomitant treatment is appropriate, prescribing information in the labeling for the other antibiotics should be followed. the dose depends on the severity of the infection and the patient’s condition. to reduce the development of drug-resistant bacteria and maintain the effectiveness of ceftazidime for injection, usp and other antibacterial drugs, ceftazidime f

Australia - English - Department of Health (Therapeutic Goods Administration)

southern xp ip pty ltd - ceftazidime pentahydrate, quantity: 1165 mg (equivalent: ceftazidime, qty 1 g) - injection, powder for - excipient ingredients: sodium carbonate; carbon dioxide - treatment of single and mixed infections caused by susceptible aerobic organisms with suspected or documented resistance to other antimicrobials, but not to ceftazidime; as an alternative to aminoglycosides in pseudomonal infection in patients in whom aminoglycoside toxicity is a cause for concern and other antipseudomonal antibiotics cannot be used. indications include the following. severe infections in general. for example: septicaemia (including neonatal sepsis), bacteraemia; in patients in intensive care units with specific problems, e.g. infected burns. respiratory tract. eg: pneumonia, bronchopneumonia, infected pleurisy, infected bronchiectasis and bronchitis. severe ear, nose and throat infections. for example: otitis media, mastoiditis. urinary tract. for example: acute and chronic pyelonephritis, pyelitis, cystitis, urethritis (bacterial only); infections associated with bladder and renal stones. skin and soft tissue. for example: erysipelas, abscesses, cellulitis, infected burns and wounds, mastitis. gastrointestinal and abdominal. for example: intra-abdominal abscesses, enterocolitis. bone and joint. for example: osteitis, osteomyelitis, septic arthritis, infected bursitis.

Israel - English - Ministry of Health

neopharm (israel) 1996 ltd - ceftazidime as pentahydrate - powder for solution for injection - ceftazidime as pentahydrate 1000 mg/vial - ceftazidime - ceftazidime is indicated for the treatment of the infections listed below in adults and children includingneonates (from birth).• nosocomial pneumonia• broncho-pulmonary infections in cystic fibrosis• bacterial meningitis• chronic suppurative otitis media• malignant otitis externa• complicated urinary tract infections• complicated skin and soft tissue infections• complicated intra-abdominal infections• bone and joint infections• peritonitis associated with dialysis in patients on capd.treatment of patients with bacteraemia that occurs in association with, or is suspected to be associated with, any of the infections listed above.ceftazidime may be used in the management of neutropenic patients with fever that is suspected to be due to a bacterial infection.ceftazidime may be used in the peri-operative prophylaxis of urinary tract infections for patients undergoing trans-urethral resection of the prostate (turp).the selection of ceftazidime should take into account its antibacterial spectrum, which is mainly restricted to aerobic gram negative bacteria (see sections 4.4 and 5.1).ceftazidime should be co-administered with other antibacterial agents whenever the possible range of causative bacteria would not fall within its spectrum of activity.consideration should be given to official guidelines regarding the appropriate use of antibacterial agents

Israel - English - Ministry of Health

neopharm (israel) 1996 ltd - ceftazidime as pentahydrate - powder for solution for inj/inf - ceftazidime as pentahydrate 2000 mg/vial - ceftazidime - ceftazidime is indicated for the treatment of the infections listed below in adults and children includingneonates (from birth).• nosocomial pneumonia• broncho-pulmonary infections in cystic fibrosis• bacterial meningitis• chronic suppurative otitis media• malignant otitis externa• complicated urinary tract infections• complicated skin and soft tissue infections• complicated intra-abdominal infections• bone and joint infections• peritonitis associated with dialysis in patients on capd.treatment of patients with bacteraemia that occurs in association with, or is suspected to be associated with, any of the infections listed above.ceftazidime may be used in the management of neutropenic patients with fever that is suspected to be due to a bacterial infection.ceftazidime may be used in the peri-operative prophylaxis of urinary tract infections for patients undergoing trans-urethral resection of the prostate (turp).the selection of ceftazidime should take into account its antibacterial spectrum, which is mainly restricted to aerobic gram negative bacteria (see sections 4.4 and 5.1).ceftazidime should be co-administered with other antibacterial agents whenever the possible range of causative bacteria would not fall within its spectrum of activity.consideration should be given to official guidelines regarding the appropriate use of antibacterial agents

Israel - English - Ministry of Health

pharmalogic ltd - ceftazidime as pentahydrate - powder for solution for inj/inf - ceftazidime as pentahydrate 1 g - ceftazidime - ceftazidime panpharma is indicated for the treatment of the infections listed below in adults and children including neonates (from birth). - nosocomial pneumonia- broncho-pulmonary infections in cystic fibrosis- bacterial meningitis- chronic supportive otitis media- malignant otitis externa- complicated urinary tract infections- complicated skin and soft issues infections- complicated intra-abdominal infections- bone and joint infections- peritonitis associated with dialysis in patients with capdtreatment of patients with bacteremia that occurs in association with, or is suspected to be associated with, any of the infections listed above.ceftazidime may be used in the management of neutropenic patients with fever that is suspected to be due to a bacterial infection.ceftazidime may be used in the peri-operative prophylaxis of urinary tract infections for patients undergoing transurethral resection of the prostate (turp).

Israel - English - Ministry of Health

pharmalogic ltd - ceftazidime as pentahydrate - powder for solution for inj/inf - ceftazidime as pentahydrate 2 g - ceftazidime - ceftazidime panpharma is indicated for the treatment of the infections listed below in adults and children including neonates (from birth). - nosocomial pneumonia- broncho-pulmonary infections in cystic fibrosis- bacterial meningitis- chronic supportive otitis media- malignant otitis externa- complicated urinary tract infections- complicated skin and soft issues infections- complicated intra-abdominal infections- bone and joint infections- peritonitis associated with dialysis in patients with capdtreatment of patients with bacteremia that occurs in association with, or is suspected to be associated with, any of the infections listed above.ceftazidime may be used in the management of neutropenic patients with fever that is suspected to be due to a bacterial infection.ceftazidime may be used in the peri-operative prophylaxis of urinary tract infections for patients undergoing transurethral resection of the prostate (turp).